初次治疗后复发的无功能垂体腺瘤的结局:来自英国两个大型中心的研究
该回顾性队列研究纳入英国两个中心237例初次治疗后复发的临床无功能垂体腺瘤(CNFA)患者,中位随访5.9年。再次复发后5年第二次再生长率为35.3%,不同处理方式差异明显;第一次复发后的处理方式是唯一影响第三次再生长风险的因子。
要点
- 复发CNFA二次再生长5年率为35.3%,监测组达63.4%,手术组36.2%,放疗组12.5%,手术联合放疗组12.7%。
- 监测组中34.8%最终接受干预;处理方式和性别是二次再生长危险因素。
- 第二次再生长后5年第三次再生长率为26.4%,处理方式是唯一危险因素。
核心结论
- 初次治疗后复发的CNFA患者仍存在相当大的肿瘤进展风险,需要长期随访;复发后的处理方式是决定该风险的主要因素,监测5年进展风险超过60%,相当数量患者最终需要干预。
研究设计与样本
- 回顾性队列研究,纳入英国两个中心237例初次治疗后复发的临床无功能垂体腺瘤(CNFA)患者。
- 中位随访5.9年(范围0.4至37.7年)。
主要发现
- 二次再生长5年率为35.3%:手术后36.2%,放疗后12.5%,手术联合放疗后12.7%,监测组63.4%。
- 监测组中34.8%最终接受干预;处理方式和性别是二次再生长危险因素。
- 第二次再生长后5年第三次再生长率为26.4%:手术后24.4%,放疗后0%,手术联合放疗后0%,监测组48.3%。
- 复发CNFA患者5年第三次再生长概率为4.4%,10年为10.0%;第一次复发的处理方式是唯一危险因素。
- 两名患者诊断为恶性转化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Despite the major risk of regrowth of clinically nonfunctioning pituitary adenomas (CNFAs) after primary treatment, systematic data on the probability of further tumor progression and the effectiveness of management approaches are lacking. OBJECTIVE: To assess the probability of further regrowth(s), predictive factors, and outcomes of management approaches in patients with CNFA diagnosed with adenoma regrowth after primary treatment. PATIENTS, DESIGN, AND SETTING: Retrospective cohort study of 237 patients with regrown CNFA managed in two UK centers. RESULTS: Median follow-up was 5.9 years (range, 0.4 to 37.7 years). The 5-year second regrowth rate was 35.3% (36.2% after surgery; 12.5% after radiotherapy; 12.7% after surgery combined with radiotherapy; 63.4% with monitoring). Of those managed with monitoring, 34.8% eventually were offered intervention. Type of management and sex were risk factors for second regrowth. Among those with second adenoma regrowth, the 5-year third regrowth rate was 26.4% (24.4% after surgery; 0% after radiotherapy; 0% after surgery combined with radiotherapy; 48.3% with monitoring). Overall, patients with a CNFA regrowth had a 4.4% probability of a third regrowth at 5 years and a 10.0% probability at 10 years; type of management of the first regrowth was the only risk factor. Malignant transformation was diagnosed in two patients. CONCLUSIONS: Patients with regrown CNFA after primary treatment continue to carry considerable risk of tumor progression, necessitating long-term follow-up. Management approach to the regrowth was the major factor determining this risk; monitoring had >60% risk of progression at 5 years, and a substantial number of patients ultimately required intervention.
引用
- Tampourlou M, Ntali G, Ahmed S, et al. Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers. J Clin Endocrinol Metab. 2017. PMID: 28323946. doi:10.1210/jc.2016-4061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。